DENGUE VIRUS VACCINE COMPOSITIONS AND METHODS OF USE THEREOF

The present invention relates to dengue virus vaccine compositions comprising a first and a second dengue vaccine, wherein the first dengue vaccine comprises at least one live, 5 attenuated dengue virus or live, attenuated chimeric dengue virus and the second dengue vaccine is a recombinant dengue s...

Full description

Saved in:
Bibliographic Details
Main Authors BETT, Andrew, DHANASEKARAN, Govindarajan, CHINTALA, Ramesh, V, COLLER, Beth-Ann Griswold, CASIMIRO, Danilo, R
Format Patent
LanguageEnglish
Published 28.07.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to dengue virus vaccine compositions comprising a first and a second dengue vaccine, wherein the first dengue vaccine comprises at least one live, 5 attenuated dengue virus or live, attenuated chimeric dengue virus and the second dengue vaccine is a recombinant dengue subunit vaccine, a DNA vaccine, a conjugate vaccine, or an inactivated dengue vaccine; wherein the genome of the live attenuated dengue virus or the live attenuated chimeric dengue virus comprises a 30 nucleotide deletion of the TL2 stem-loop structure of the 3′ untranslated region. The dengue virus vaccine compositions of the invention may further 10 comprise one or more adjuvants. In preferred embodiments of the invention, the first and the second dengue vaccine are tetravalent. The invention also relates to methods of using the dengue virus vaccine compositions of the invention to treat or prevent dengue infection, or to prevent, ameliorate, or delay the onset or progression of the clinical manifestations thereof.
Bibliography:Application Number: SG20171104942Q